arrow
E

Edyta Subocz

Nicolaus Copernicus University
H指数:12
被引数:523

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

No advantage of antimicrobial prophylaxis in AML/MDS/CMML patients treated with azacitidine-a prospective multicenter study by the Polish Adult Leukemia Group
2024-06-130
OAAI
Identification of novel genetic loci for risk of multiple myeloma by functional annotation
LEUKEMIA
IF13.4
2023-09-182
OAAI
A pleiotropic variant in DNAJB4 is associated with multiple myeloma risk
2022-10-010
OA
Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients
2022-07-2716
OA
Does a Multiple Myeloma Polygenic Risk Score Predict Overall Survival of Patients with Myeloma?
2022-06-143
PRE
A polygenic risk score for multiple myeloma risk prediction
2021-11-306
OAAI
Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group

基于苯达莫司汀的方案作为难治性/复发性多发性骨髓瘤患者的挽救治疗: 波兰骨髓瘤组的回顾性现实分析

2021-11-243
OAAI
Genetically determined telomere length and multiple myeloma risk and outcome
2021-04-1412
OAAI
Expression quantitative trait loci of genes predicting outcome are associated with survival of multiple myeloma patients
2021-03-305
OAAI
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma (February, 10.1007/s00277-021-04448-5, 2021)
2021-03-240
OAAI
High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin Lymphoma

BGD (苯达莫司汀,吉西他滨和地塞米松) 在复发/难治性霍奇金淋巴瘤中的高疗效

2021-02-241
OAAI
Common gene variants within 3′-untranslated regions as modulators of multiple myeloma risk and survival
2020-11-203
OAAI
Hodgkin lymphoma transformation of chronic lymphocytic leukemia-A real life data from the Polish Lymphoma Research Group
2019-06-144
PREAI
The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study

第一个化疗周期后中期PET的预测作用和对霍奇金淋巴瘤患者ABVD反应的顺序评估-波兰淋巴瘤研究组 (PLRG) 观察性研究

2017-12-0114
OAAI
Prognostic impact of NOTCH1, MYD88, and SF3B1 mutations in Polish patients with chronic lymphocytic leukemia

NOTCH1,MYD88和SF3B1突变对波兰慢性淋巴细胞白血病患者的预后影响

2017-04-2013
PRE
Prognostic Value of Bone Marrow Tracer Uptake Pattern in Baseline PET Scans in Hodgkin Lymphoma: Results from an International Collaborative Study
2017-01-2620
OAAI
Identification of miRSNPs associated with the risk of multiple myeloma

与多发性骨髓瘤风险相关的miRSNPs的鉴定

2016-11-098
OAAI
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study
2016-10-0156
PREAI